Vicente Alonso
About
Vicente Alonso is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology.
According to data from OpenAlex, Vicente Alonso has authored 107 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 26 papers in Epidemiology. Recurrent topics in Vicente Alonso's work include Colorectal Cancer Treatments and Studies (56 papers), Colorectal Cancer Surgical Treatments (28 papers) and Neuroendocrine Tumor Research Advances (26 papers). Vicente Alonso is often cited by papers focused on Colorectal Cancer Treatments and Studies (56 papers), Colorectal Cancer Surgical Treatments (28 papers) and Neuroendocrine Tumor Research Advances (26 papers). Vicente Alonso collaborates with scholars based in Spain, United States and United Kingdom. Vicente Alonso's co-authors include Carles Pericay, Joan Maurel, P. Escudero, Antonieta Salud, Carlos Fernández-Martos, Jorge Aparicio, Ruth Vera, Bartomeu Massutí, Rocio García‐Carbonero and Xabier García‐Albéniz and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Clinical Cancer Research.
In The Last Decade
Vicente Alonso
100 papers receiving 1.7k citations
Peers
Vicente Alonso
Kevin Norwood United States
Natsuko Okita Japan
Roopinder Gillmore United Kingdom
Olivier Dubreuil France
Antonio Cubillo Spain
Ke‐Neng Chen China
Renée van Pel Netherlands
Tyler P. Robin United States
J. F. Gigot Belgium
Catherine Kennedy Australia
Citations per year, relative to Vicente Alonso Vicente Alonso (= 1×)
peers
Kevin Norwood
Countries citing papers authored by Vicente Alonso
Since
Specialization
Citations
This map shows the geographic impact of Vicente Alonso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vicente Alonso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vicente Alonso more than expected).
Fields of papers citing papers by Vicente Alonso
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Vicente Alonso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vicente Alonso. The network helps show where Vicente Alonso may publish in the future.
Co-authorship network of co-authors of Vicente Alonso
This figure shows the co-authorship network connecting the top 25 collaborators of Vicente Alonso. A scholar is included among the top collaborators of Vicente Alonso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vicente Alonso. Vicente Alonso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Alonso, Vicente, et al.. (2025). Evaluation of the Real-Life Efficacy and Safety of the Treatment with Lutetium-177 Dotatate for Metastatic Neuroendocrine Tumors. Journal of Clinical Medicine. 14(7). 2384–2384.
2.
Martínez, María Carmen Riesco, Jaume Capdevila, Vicente Alonso, et al.. (2024). Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913). Nature Communications. 15(1). 6753–6753.
3.
García‐Carbonero, Rocio, Carles Pericay, Ana Fernández Montés, et al.. (2023). Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain. Clinical & Translational Oncology. 26(4). 864–871.
4.
Vidal, Joana, David Casadevall, Beatríz Bellosillo, et al.. (2021). Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial. Clinical Cancer Research. 27(10). 2890–2898.
5.
Capdevila, Jaume, Àlex Teulé, Carlos López, et al.. (2020). 1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601). Annals of Oncology. 31. S770–S771.
6.
Vera, Ruth, Elena Mata, Encarnación González‐Flores, et al.. (2020). Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?. International Journal of Colorectal Disease. 35(4). 739–746.
7.
Carmona‐Bayonas, Alberto, Rocio García‐Carbonero, Ana Custodio, et al.. (2019). Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). British Journal of Cancer. 121(7). 537–544.
8.
Barriuso, Jorge, Ana Custodio, Vicente Alonso, et al.. (2018). Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. Cancer Treatment Reviews. 70. 209–222.
9.
Alonso, Vicente, Javier Gállego, José Ramón Rodríguez, et al.. (2016). Prospective evaluation of BRAF, PI3K and PTEN as predictive and prognostic biomarkers in first-line advanced KRAS wild-type colorectal cancer treated with FOLFOX or FOLFIRI plus bi-weekly cetuximab. GEMCAD 10-02. Annals of Oncology. 27. vi178–vi178.
10.
Capdevila, Jaume, Isabel Sevilla, Vicente Alonso, et al.. (2015). Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 15(1). 495–495.
11.
Sotelo, Miguel J., Javier Sastre, M.L. Maestro, et al.. (2014). Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Annals of Oncology. 26(3). 535–541.
12.
Martín-Richard, Marta, Bartomeu Massutí, Vicente Alonso, et al.. (2013). Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer. 13(1). 427–427.
13.
Codony‐Servat, Jordi, Xabier García‐Albéniz, Carles Pericay, et al.. (2013). Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer. Medical Oncology. 30(1). 428–428.
14.
Castellano, Daniel, Jaume Capdevila, Javier Sastre, et al.. (2013). Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). European Journal of Cancer. 49(18). 3780–3787.
15.
Diaz, E., et al.. (2012). P-902 - Depression caused by primary hyperparathyroidism with hypercalcemia: a case report. European Psychiatry. 27. 1–1.
16.
Salazar, Ramón, Matilde Navarro, Ferrán Losa, et al.. (2012). Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II–III rectal cancer. Clinical & Translational Oncology. 14(8). 592–598.
17.
Alonso, Vicente, Carles Pericay, P. Escudero, et al.. (2010). Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer. Chemotherapy. 56(2). 142–146.
18.
Abad, Albert, Bartomeu Massutí, Antonio Antón, et al.. (2008). Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. Acta Oncologica. 47(2). 286–292.
19.
Molina, Inmaculada, et al.. (2006). Infección subcutánea necrotizante por Streptococcus agalactiae. Actas Dermo-Sifiliográficas. 97(10). 644–646.
20.
Martínez‐Trufero, Javier, Juan Lao, Teresa Puértolas, et al.. (2005). Serum Markers and Prognosis in Locally Advanced Breast Cancer. Tumori Journal. 91(6). 522–530.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kevin Norwood Breakdown of academic impact, for papers by Natsuko Okita Breakdown of academic impact, for papers by Roopinder Gillmore Breakdown of academic impact, for papers by Olivier Dubreuil Breakdown of academic impact, for papers by Antonio Cubillo Breakdown of academic impact, for papers by Ke‐Neng Chen Breakdown of academic impact, for papers by Renée van Pel Breakdown of academic impact, for papers by Tyler P. Robin Breakdown of academic impact, for papers by J. F. Gigot Breakdown of academic impact, for papers by Catherine Kennedy